Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

CCND1 expression

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

ALK fusion + MYC amplification + CCND1 deletion + FGFR3 deletion (1)

ALK positive + MYC amplification + CCND1 deletion (1)

CCND1 mutation + HR positive (1)

EGFR exon 19 deletion + CCND1 overexpression (1)

EGFR mutation + CCND1 expression + CDKN2A deletion (1)

ER L536H + ER D538G + CCND1 amplification (1)

ER positive + ESR1 mutation + CCND1 amplification (1)

HR positive + CCND1 amplification (1)

ALK fusion + MYC amplification + CCND1 deletion + FGFR3 deletion (1)

ALK positive + MYC amplification + CCND1 deletion (1)

CCND1 mutation + HR positive (1)

EGFR exon 19 deletion + CCND1 overexpression (1)

EGFR mutation + CCND1 expression + CDKN2A deletion (1)

ER L536H + ER D538G + CCND1 amplification (1)

ER positive + ESR1 mutation + CCND1 amplification (1)

HR positive + CCND1 amplification (1)

›

CCND1 expression	Non Small Cell Lung Cancer	CCND1 expression	Non Small Cell Lung Cancer	erlotinib Sensitive: C2 – Inclusion Criteria erlotinib Sensitive : C2	erlotinib Sensitive: C2 – Inclusion Criteria erlotinib Sensitive : C2
CCND1 expression	Diffuse Large B Cell Lymphoma	CCND1 expression	Diffuse Large B Cell Lymphoma	Resistant: C3 – Early Trials Resistant : C3	Resistant: C3 – Early Trials Resistant : C3
CCND1 expression	Mantle Cell Lymphoma	CCND1 expression	Mantle Cell Lymphoma	palbociclib Sensitive: D – Preclinical palbociclib Sensitive : D	palbociclib Sensitive: D – Preclinical palbociclib Sensitive : D
CCND1 expression	Multiple Myeloma	CCND1 expression	Multiple Myeloma	venetoclax Sensitive: D – Preclinical venetoclax Sensitive : D	venetoclax Sensitive: D – Preclinical venetoclax Sensitive : D